December 10, 2018
Most Innovative European Biotech SME for 2018
Most Innovative European Biotech SME for 2018 Bruxelles, Belgium, December 3, 2018 - Company…
Read More
October 5, 2018
Extension to US of GNS561 Clinical Trial
Genoscience Pharma Extends to US its Clinical Trial in Patients with Advanced Liver Cancers …
Read More
June 4, 2018
S.A.B. Meeting in Chicago, during ASCO 2018
Scientific Advisory Board Meeting during ASCO 2018 Chicago, USA, June 4, 2018 — During…
Read More
May 22, 2018
Extension to France of GN561 Clinical trial
Genoscience Pharma Extends its GNS561 Clinical Trial to France Enrollment is open for patients…
Read More
April 5, 2018
First-in-human Dosing of GNS561 in Liver Cancer Patients
First-in-human Dosing of GNS561 in Patients with Advanced Liver Cancer at the Jules Bordet Institute,…
Read More
December 6, 2017
GNS561 Gets US FDA IND Approval in Liver Cancer
Genoscience Pharma Receives FDA Approval for Phase Ib/IIa Study of GNS561 in Liver Cancer …
Read More
February 24, 2016
Four New Members in Our Directory Board
Four New Members in Our Directory Board Marseille, France, February 24, 2016 – Genoscience Pharma…
Read More
February 6, 2012
BL-8030 worldwide License Agreement with BioLineRx
RFS Pharma and Genoscience Pharma enter Worldwide License Agreement with BioLineRx to develop and commercialize Hepatitis…
Read More
January 24, 2012
BL-8020 exclusive License Agreement with BioLineRx
BioLineRx signs exclusive License Agreement for BL-8020, an oral Hepatitis C treatment Jerusalem, Israel,…
Read More
June 19, 2007
Joint Venture Agreement with RFS Pharma
RFS Pharma and Genoscience Pharma Sign Joint Venture Agreement to Discover and Develop Protease Inhibitors…
Read More
